The therapeutic alliance is considered an important causal agent of psychotherapy efficacy. However, studies in cognitive behavioral therapy (CBT) for depression have suggested that alliance might be more of a consequence rather than a cause of depressive symptom change, while adherence to CBT specific techniques was found to be associated with subsequent depression change. We aimed to add to this body of literature by assessing the temporal associations of both therapeutic alliance and manual adherence with depressive symptom change in a relatively large sample of depressed adult outpatients over the full course of CBT. Adults with a major depressive episode ( = 98) participating in a randomized clinical trial were offered 22 weeks of CBT and rated the Penn Helping Alliance Questionnaire (HAq-I) at weeks 5 and 22. Therapists rated their adherence to the CBT manual after each session and observers assessed the Hamilton Depression Rating Scale scores at weeks 0, 5, 10, and 22. Linear mixed model analyses were used to assess the associations of alliance and adherence with prior and subsequent depression change. HAq-I Relationship and manual adherence ratings were not significantly associated with prior nor with subsequent depression change ( > 0.14). Prior depression change was associated with the HAq-I subscale Perceived helpfulness at the end of treatment ( = 0.30, CI = 0.03-0.56, = 0.03). We were not able to replicate prior depression change in CBT for depression to be associated with improved quality of the therapeutic alliance when using a more "pure" measure of the therapeutic relationship. Limitations of this study include the subjective alliance and adherence assessments. Our findings indicate the need to appropriately distinguish between the perceived helpfulness and the relationship factors when examining therapeutic alliance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838346 | PMC |
http://dx.doi.org/10.3389/fpsyt.2020.602294 | DOI Listing |
BJPsych Open
January 2025
ICOnnecta't Digital Health Program, Catalan Institute of Oncology, Hospitalet del Llobregat, Spain; Psychooncology and Digital Health Group, The Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Spain; and Department of Clinical Psychology and Psychobiology, Universitat de Barcelona, Spain.
Background: Action mechanisms of therapeutic alliance in stepped and digital interventions remain unclear.
Aims: (a) To compare the development of therapeutic alliance between psychosocial treatment as usual (PTAU) and a stepped digital intervention designed to prevent distress in cancer patients; (b) to analyse the level of agreement between patients' and therapists' therapeutic alliance ratings; and (c) to explore variables associated with therapeutic alliance in the digital intervention.
Method: A multicentre randomised controlled trial with 184 newly diagnosed breast cancer women was conducted.
Early Interv Psychiatry
February 2025
Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA.
Background: Fostering positive relationships with mental health professionals and involving family in treatment can reduce untreated psychosis duration and prevent dropout.
Aims: The present study explores the experiences of young adults with psychosis as they engage in mental health treatment and communicate with family caregivers. Describing their lived experiences would inform the clinical engagement process and pathways to clinical outcomes.
Curr Opin Psychol
January 2025
Department of Rehabilitation Medicine, The University of Washington, Seattle, WA, USA.
Psychological chronic pain treatments have variable efficacy across individual patients, and on average tend to produce modest effects. In order to improve treatment outcomes, the past decade has seen a rapid increase in research focused on determining the mechanisms underlying treatment-related gains. The near exclusive focus of this research has been on uncovering patient-related mediators and moderators.
View Article and Find Full Text PDFLancet Neurol
February 2025
Department of Medicine, McMaster University, Population Health Research Institute, Hamilton, ON, Canada.
Background: People with subclinical atrial fibrillation are at increased risk of stroke, albeit to a lesser extent than those with clinical atrial fibrillation, leading to an ongoing debate regarding the benefit of anticoagulation in these individuals. In the ARTESiA trial, the direct-acting oral anticoagulant apixaban reduced stroke or systemic embolism compared with aspirin in people with subclinical atrial fibrillation, but the risk of major bleeding was increased with apixaban. In a prespecified subgroup analysis of ARTESiA, we tested the hypothesis that people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack, who are known to have an increased risk of recurrent stroke, would show a greater benefit from oral anticoagulation for secondary stroke prevention compared with those without a history of stroke or transient ischaemic attack.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!